Tandem Diabetes Care Inc. (TNDM)

Tandem Diabetes Care (TNDM) reported earnings 30 days ago. What's next for the stock?

Investors remain optimistic about TNDM, courtesy of its strong t:slim X2 performance and breakthrough innovations.

Tandem Diabetes' Q1 bottom line lags estimate. However, the company experiences strong sales growth both in and outside the United States.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Susan Morrison - EVP & Chief Administrative Officer John Sheridan - President ...

Although the revenue and EPS for Tandem Diabetes Care (TNDM) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with...

Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.63 per share a year ago.

Here is a sneak peek into how these three MedTech stocks, ALGN, TNDM and ICLR, may fare in their quarterly results, slated to be released tomorrow.

A robust diabetes market and international expansion raise investors' optimism for Tandem Diabetes.

The global demographic shift is reshaping healthcare demand, driving long-term investment in pharmaceuticals, medical devices, home care and digital health.

With equity markets reeling due to President Donald Trump's tariffs, many investors are taking this opportunity to buy shares of top companies on the dip. It's a great strategy, but it's essential to ...